PharmaMar

PharmaMar Reports Positive Results from the Phase I Study of Aplidin (plitidepsin) in Combination with bortezomib and dexamethasone in Patients with Multiple Myeloma at the 2016 ASCO Annual Meeting

MADRID, May 19, 2016 /PRNewswire The data will be presented in an oral session (abstract #8006) The conclusions of the study point to a response rate of 56% of the treated patients with 90% of them presenting duration of response (DOR) of six months or more. Seventy two percent of the patients had clinical benefit....

PharmaMar Announces New Data on Yondelis, Aplidin and PM1183 to be Presented at 2016 ASCO Annual Meeting

PharmaMar announced today that data obtained from various clinical studies carried out with three of its antitumoral compounds of marine origin - Yondelis, Aplidin and PM1183 - will be presented during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3 - 7.
Avda. De los Reyes, 1. Pol. Ind. La Mina 28770 – Colmenar Viejo Madrid, CIF: A-78267176, Spain

91 846 6000